martes, 28 de enero de 2014

National Guideline Clearinghouse | Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis.

full-text ►

National Guideline Clearinghouse | Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis.



National Institute for Health and Care Excellence (NICE)

National Guideline Clearinghouse (NGC)

January 27, 2014

Guideline Title
Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis.
Bibliographic Source(s)
National Institute for Health and Care Excellence (NICE). Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Jun. 61 p. (Technology appraisal guidance; no. 289). 
Guideline Status
This is the current release of the guideline.

No hay comentarios:

Publicar un comentario